Paul M. Bingham
Stony Brook University
52 Papers
1.6K Citations
Paul M. Bingham is an academic researcher from Stony Brook University. The author has contributed to research in topics: Locus (genetics) & Gene. The author has an hindex of 29, co-authored 51 publications. Previous affiliations of Paul M. Bingham include Harvard University & National Institutes of Health.
Chat about Author
Papers
The molecular basis of P-M hybrid dysgenesis: the nature of induced mutations.
TL;DR: The molecular nature of mutations arising in dysgenic hybrids between P and M Drosophila melanogaster strains has been investigated and members of this sequence family are referred to as P elements.
511
The chromatin structure of specific genes: I. Evidence for higher order domains of defined DNA sequence
TL;DR: Restriction enzyme cleavage of the fragments generated indicates that the preferential DNAase I cleavage sites in chromatin are position-specific, and this nuclease also cleaves at position- specific sites.
438
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Zuzana Zachar,James F. Marecek,Claudia Maturo,Sunita Gupta,Shawn D. Stuart,Katy Howell,Alexandra Schauble,Joanna Lem,Arin Piramzadian,Sameer Karnik,King Lee,Robert J. Rodriguez,Robert Shorr,Paul M. Bingham +13 more
TL;DR: In this paper, a set of analogs of lipoic acid (lipoate) have been investigated as potential anticancer agents, including CPI-613, which is shown to be effective against human non-small cell lung and pancreatic cancers in xenograft models.
200
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Tatiana Alistar,Bonny Morris,Rodwige Desnoyer,Heidi D. Klepin,Keyanoosh Hosseinzadeh,Clancy J. Clark,Amy Cameron,John R. Leyendecker,Ralph B. D'Agostino,Umit Topaloglu,Lakmal W. Boteju,Asela R Boteju,Rob Shorr,Zuzana Zachar,Paul M. Bingham,Tamjeed Ahmed,Sandrine Crane,Riddhishkumar Shah,John J Migliano,Timothy S. Pardee,Lance D. Miller,Gregory A. Hawkins,Guangxu Jin,Wei Zhang,Boris Pasche +24 more
TL;DR: The primary objective was to establish the maximum tolerated dose of CPI-613 (as assessed by dose-limiting toxicities) in patients with newly diagnosed metastatic pancreatic adenocarcinoma.
On/off regulation of gene expression at the level of splicing.
TL;DR: The past two years have seen the discovery of three independent cases in which expression of a eukaryotic protein gene product is turned on and off by controlling splicing events necessary to produce the corresponding mRNA.
180